| Reduced | Cancelled | Delayed | |
|---|---|---|---|
| Oxaliplatin (n = 58, 73.4%) | 32.8% | 32.8% | 32.8% |
| 5-Fluorouracil (n = 47, 59.4%) | 38.3% | 27.7% | 59.6% |
| Capecitabine (n = 31, 39.2%) | 19.4% | 22.6% | 32.3% |
| Bevacizumab (n = 44, 55.7%) | 27.3% | 36.4% | 47.7% |
| Cetuximab/Panitumumab (n = 12, 15.2%) | 58.3% | 8.3% | 75% |